Protein Nanocage Folic Acid Modification
Folic acid (FA) has been used in targeting tumors as it binds the folate receptor (FR) overexpressed in cancerous cells and is internalized through receptor-mediated endocytosis. In many studies, FA conjugated nanocages have been used as a targeted carrier to cancer cells.[1] Now, Creative BioMart Nanocage can offer you with professional protein nanocage folic acid modification service according to your scientific needs, if you have any needs in this regard, please feel free to contact us.
Research progress in DNA nanocage drug delivery
Zeng et al. [2] used CMV decorated with 180 FA to deliver dox to ovarian tumor tissue in in vivo models. This FA-CMV can load a significant amount of dox, 1500 molecules, into the interior cavity through the formation of Dox-RNA conjugate. Both in vitro and in vivo analysis of FA-CMV-dox particles showed increased accumulation in targeted tumor cells than without FA, thus the results showed stronger tumor regression as well as lower cardiotoxicity. Other receptors are also targeted, for instance asialoglycoprotein receptors (ASGPRs), of hepatocytes or hepatoma cells. Lactobionic acid (LA), used for specific targeting to ASGPRs, was decorated on a rotavirus capsid VP6 up to 1560 molecules, by the four lysine residues on the surface of the cage. This resulted in greatly enhanced receptor-mediated endocytosis in HepG2 cell.

Nanocage Folic Acid Modification We Offer
Creative BioMart Nanocage focuses on comprehensive services for protein folic acid modification. Creative BioMart Nanocage has well-trained technicians and the most advanced nano cage modification technology to meet your scientific research needs. The modified molecules we can provide include but are not limited to:

- Creative BioMart Nanocage provides professional protein nanocage folic acid modification services. The modified DNA nanocage can specifically target folate receptors on the surface of tumor cells.
- Creative BioMart Nanocage utilizes the unique structural features of protein nanocages. We anchor folic acid (FA) as the targeting moiety to rigid protein nanocages, and provide nano-scale controlled delivery systems for cancer treatment by forming nanocage-folic acid conjugates.
- We modify the DNA nanocage with folic acid, which can not only improve the surface characteristics of the protein nanocage, but also enhance the targeting ability and significantly improve the anti-tumor effect.
Our Advantages
- Creative BioMart Nanocage specializes in protein nanocage modification service and we are committed to contributing to more customers.
- Creative BioMart Nanocage cooperates with scientists from many pharmaceutical and biotechnology companies. We have a wealth of knowledge and experience to provide quality assurance services.
- Creative BioMart Nanocage will complete your project on time and efficiently. We have professional after-sales service: which has been established to provide customers with efficient, fast, practical and feasible solutions.
Service Procedure

Please inform us of your protein nanocage folic acid modification project details through online consultation. We will reply to you in time and provide you with a comprehensive evaluation report on your project.
Why choose us?
Creative BioMart Nanocage provides professional protein nanocage folic acid modification service to meet the scientific research needs of customers. Creative BioMart Nanocage relies on world-class technical expertise, we provide customers with the best quality one-stop protein nanocage folic acid modification, including the development of experimental procedures according to different experimental needs. Please feel free to contact us for more detailed information, our scientists will tailor the most reasonable plan for your project.
References
- Sokolov A V, Kostin N N, Ovchinnikova L A , et al. Targeted Drug Delivery in Lipid-like Nanocages and Extracellular Vesicles. Acta Naturae, 2019, 11(41):28-37.
- Q.B. Zeng, H.B. Wen, Q. Wen, X.H. Chen, Y.G. Wang, W.L. Xuan, J.S. Liang, S.H. Wan, Cucumber mosaic virus as drug delivery vehicle for doxorubicin, Biomaterials, 2013,34: 4632-4642.